Ser161
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser161  -  ERF (human)

Site Information
sPtEDPRsPPACssS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 456969
Available spectra:  3 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 13 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ) , mutation of modification site ( 13 ) , phosphopeptide mapping ( 13 )
Disease tissue studied:
breast cancer ( 2 ) , lung cancer ( 3 , 4 , 5 , 6 , 7 , 8 ) , non-small cell lung cancer ( 3 , 4 , 5 , 7 , 8 , 9 , 10 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 5 , 6 , 7 , 8 , 10 ) , non-small cell large cell lung carcinoma ( 4 , 7 ) , non-small cell squamous cell lung carcinoma ( 6 ) , melanoma skin cancer ( 1 )
Relevant cell line - cell type - tissue:
3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 13 ) , A549 (pulmonary) ( 3 ) , Calu-3 (pulmonary) ( 5 ) , DMS153 (pulmonary) ( 8 ) , HCC15 (pulmonary) ( 6 ) , HCC78 (pulmonary) ( 7 ) , HCC827 (pulmonary) ( 5 ) , HeLa (cervical) ( 11 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 2 ) , HMLER ('stem, breast cancer') ( 2 ) , LOU-NH91 (squamous) ( 6 ) , lung ( 3 , 4 , 5 , 6 , 7 , 8 ) , NCI-H1299 (pulmonary) ( 4 ) , NCI-H1355 (pulmonary) ( 3 ) , NCI-H1437 (pulmonary) ( 8 ) , NCI-H1650 (pulmonary) ( 5 ) , NCI-H1703 (squamous) ( 6 , 12 ) , NCI-H1734 (pulmonary) ( 4 ) , NCI-H1781 (pulmonary) ( 7 ) , NCI-H1792 (pulmonary) ( 3 ) , NCI-H1944 (pulmonary) ( 4 ) , NCI-H1975 (pulmonary) ( 5 ) , NCI-H2073 (pulmonary) ( 6 , 8 ) , NCI-H209 (pulmonary) ( 8 ) , NCI-H2106 (pulmonary) ( 5 ) , NCI-H2228 (pulmonary) ( 7 , 10 ) , NCI-H23 (pulmonary) ( 3 ) , NCI-H2342 (pulmonary) ( 6 ) , NCI-H3122 (pulmonary) ( 7 , 9 ) , NCI-H358 (pulmonary) ( 4 ) , NCI-H441 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 4 ) , NCI-H661 (pulmonary) ( 7 ) , NCI-H838 (pulmonary) ( 8 ) , WM239A (melanocyte) ( 1 )

Upstream Regulation
Putative in vivo kinases:
ERK2 (human) ( 13 )
Kinases, in vitro:
ERK2 (human) ( 13 )
Treatments:
PD98059 ( 13 ) , selumetinib ( 1 ) , serum ( 13 ) , vemurafenib ( 1 )

Downstream Regulation
Effects of modification on ERF:
intracellular localization ( 13 )
Effects of modification on biological processes:
cell cycle regulation ( 13 )

References 

1

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

2

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K (2013) CST Curation Set: 18860; Year: 2012; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

10

Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

11

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

12

Possemato A (2006) CST Curation Set: 1665; Year: 2006; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

13

Le Gallic L, Sgouras D, Beal G, Mavrothalassitis G (1999) Transcriptional repressor ERF is a Ras/mitogen-activated protein kinase target that regulates cellular proliferation. Mol Cell Biol 19, 4121-33
10330152   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.